•
Jun 30, 2024

Allurion Q2 2024 Earnings Report

Reported strong sequential revenue growth and record procedure volume.

Key Takeaways

Allurion Technologies, Inc. announced its Q2 2024 financial results, highlighted by a sequential revenue increase of $2.4 million from Q1 2024, reaching $11.8 million, and a 12% year-over-year growth in procedure volume. The company's loss from operations decreased by 30% compared to the previous year, and they updated their full-year 2024 revenue guidance to between $40 million and $45 million.

Second quarter revenue reached $11.8 million, a sequential increase of $2.4 million or 25% from the first quarter of 2024.

Second quarter loss from operations reduced by 30% compared to the year-ago period and by 44% when one-time financing costs are excluded.

Procedure volume grew by 12% year-over-year, a quarterly record that equated to over 10,000 Allurion balloon placements for the second consecutive quarter.

Full-year 2024 revenue guidance updated to between $40 million and $45 million.

Total Revenue
$11.8M
Previous year: $13M
-9.2%
EPS
-$0.05
Previous year: -$0.84
-94.0%
Gross Profit
$8.99M
Previous year: $9.97M
-9.8%
Cash and Equivalents
$19.3M
Previous year: $4.74M
+306.5%
Free Cash Flow
-$9.36M
Previous year: -$9.83M
-4.8%
Total Assets
$46.6M
Previous year: $52.2M
-10.7%

Allurion

Allurion

Forward Guidance

Allurion is updating its full-year 2024 revenue guidance to between $40 million and $45 million and expects growth in procedure volume to be between 10% and 15%.

Challenges Ahead

  • Disruption of sales in France due to regulatory suspension.
  • More conservative assumptions on inventory stocking.
  • Macroeconomic headwinds in other regions.
  • Slower growth expected in the second half of 2024.
  • Reductions in sales to certain accounts to manage credit risk.